Aptevo

$31.52
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.99 (-3.05%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Aptevo and other stocks, options, and ETFs commission-free!

About APVO

Aptevo Therapeutics Inc. Common Stock, also called Aptevo, is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded on February 22, 2016 and is headquartered in Seattle, WA. The listed name for APVO is Aptevo Therapeutics Inc. Common Stock.

CEO
Marvin L. White
Employees
80
Headquarters
Seattle, Washington
Founded
2016
Market Cap
144.68M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
74.98K
High Today
$33.09
Low Today
$31.04
Open Price
$32.51
Volume
94.08K
52 Week High
$60.00
52 Week Low
$2.94

Collections

APVO News

MarketWatchJan 16

Aptevo Therapeutics Inc. Stock Quote (U.S.: Nasdaq)

Aptevo Therapeutics Inc. Aptevo Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, commercialization, and sale of nove

APVO Earnings

-$2.41
-$1.61
-$0.80
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 25, After Hours

You May Also Like

IBDR
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure